Survival curves of PCNSL with disease responsive to MATRix chemoimmunotherapy. PFS (A) and OS (B) curves of PCNSL patients with disease responsive to a MATRix regimen and consolidated with WBRT (dotted lines) or HDC/ASCT (continuous lines) in the IELSG32 trial.³⁷